Shulman DeMeo Asset Management LLC Sells 453 Shares of Johnson & Johnson (NYSE:JNJ)

Shulman DeMeo Asset Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,247 shares of the company’s stock after selling 453 shares during the period. Johnson & Johnson accounts for 0.3% of Shulman DeMeo Asset Management LLC’s holdings, making the stock its 25th biggest holding. Shulman DeMeo Asset Management LLC’s holdings in Johnson & Johnson were worth $1,193,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of JNJ. Werlinich Asset Management LLC grew its stake in Johnson & Johnson by 1.5% in the fourth quarter. Werlinich Asset Management LLC now owns 13,330 shares of the company’s stock valued at $1,911,000 after purchasing an additional 200 shares during the last quarter. Cohen Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 2.6% in the 4th quarter. Cohen Investment Advisors LLC now owns 19,530 shares of the company’s stock valued at $2,824,000 after buying an additional 490 shares in the last quarter. Congress Park Capital LLC grew its position in shares of Johnson & Johnson by 16.4% in the 4th quarter. Congress Park Capital LLC now owns 8,153 shares of the company’s stock worth $1,179,000 after buying an additional 1,151 shares during the last quarter. Inspirion Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 7.3% during the 4th quarter. Inspirion Wealth Advisors LLC now owns 1,775 shares of the company’s stock worth $260,000 after acquiring an additional 120 shares in the last quarter. Finally, Tallon Kerry Patrick acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $290,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Guggenheim increased their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Wells Fargo & Company raised their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $174.29.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $147.03 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. The stock has a 50-day simple moving average of $148.68 and a two-hundred day simple moving average of $155.96.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.66 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.